Contenido: 325 mg x 30 comprimidos (9,75 g) Qu es
The most frequently reported adverse events were gastrointestinal events, including nausea, vomiting, diarrhea, constipation, or abdominal pain, which affected 79.6% of participants in the cagrilintide-semaglutide group and 39.9% of those in the placebo group
You may wish to discuss testing with a healthcare professional if you: Experience ongoing unexplained fatigue Follow a vegan or vegetarian diet Have a history of gastrointestinal surgery or digestive conditions Have previously been diagnosed with low B12 Have symptoms such as numbness, tingling, or cognitive changes Testing helps determine whether B12 injections are appropriate or whether another cause should be investigated
The Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed
Phospholipids are metabolized, utilized, or excreted